01
Product and partner review
Four specialist teams — medical, regulatory, supply chain and market — contribute structured assessments. Over 80 products systematically evaluated to date.
European Pharmaceutical Group
Connecting European healthcare resources with China's future
Shuaizhijia Group focuses on pharmaceutical partnerships, commercialization and life-health services for enterprise clients, investors and consumers.
2018
Founded
12+
Countries covered
680+
Employees
40+
Product lines
Shuaizhijia Group
Business Areas
Core capabilities from international cooperation to local commercialization.
Operating Model
Disciplined cross-border execution
Shuaizhijia Group
Group Strengths
We bring together European quality systems, pharmaceutical industry resources and China market execution capability. A partner network spanning Germany, France and the Nordics, combined with local teams across northern, eastern and southern China, helps partners enter and serve the market within a robust compliance framework.
Compliance first
Every project advances through clear boundaries and traceable workflows. Our internal review mechanism covers regulatory, quality, supply and commercial dimensions — ensuring each step withstands scrutiny.
Cross-border coordination
We connect European product, R&D and quality teams with China's market and service networks. Bilingual project management and bi-weekly milestone syncs keep cross-timezone collaboration transparent and rhythmic.
Long-term operation
We pursue sustainable partnerships, organizational capability and durable market trust rather than short-term visibility. Every product gets a three-year commercialization roadmap — regulatory approval is the starting line, not the finish.
Shuaizhijia Group
A Long-Term Method From Review to Operation
We turn international cooperation into clear, reviewable and deliverable steps that make professional judgment operational.
02
Market entry planning
Based on product characteristics and competitive landscape, we build complete plans covering registration paths, access strategy, channel design, academic promotion and regional execution, with quantifiable stage-gate milestones.
03
Local commercialization
Local teams across three major regions, a proven quality management system and a 120+ channel partner network drive ongoing operations, market feedback collection and strategy iteration.
Shuaizhijia Group
Latest News
Company · 2026-05-10
Shuaizhijia Group signs strategic MOU with Nordic pharmaceutical company
The partnership will cover product introduction, registration coordination and commercialization in cardiovascular therapeutics.
Industry · 2026-04-28
China regulatory reform opens new window for cross-border pharma partnerships
NMPA's latest policies shorten review timelines for certain imported drugs, offering clearer scheduling for cross-border partners.
Company · 2026-04-18
Shuaizhijia Group upgrades European partnership platform
The platform will use the Beijing Changping Vanke Sky City office hub to improve coordination across product partnerships, regulatory affairs and commercialization.
Industry · 2026-03-29
Cross-border pharma supply chains enter a new quality-and-efficiency era
Compliance, traceability and reliable delivery are becoming core partner selection criteria.
Company · 2026-03-15
RegPath Navigator regulatory platform completes beta and goes live
The platform initially serves 5 active partnership projects spanning registration planning, regulatory tracking and bilingual documentation.
Media · 2026-02-28
Interview: How Shuaizhijia Group puts pharmaceutical 'long-termism' into practice
From three-year commercialization roadmaps to sustained compliance investment, the leadership explains their methodology for long-term partnership building.
Media · 2026-02-14
Media spotlight: How a European-backed group serves China's healthcare market
Leadership discussed the Beijing hub, global resources, local teams and long-term commitment.
Industry · 2026-01-20
2025 in review: Five trends shaping cross-border pharma supply chains
Digital traceability, cold-chain upgrades, compliance-by-design, regional coordination and risk diversification defined the year.